The company said, “We expect revenues of approximately $116 million to $120 million for the full year 2023. This expected growth anticipates an approximate 4 percentage point headwind from discontinued products. For the year 2023, we expect gross margins of approximately 60% and adjusted EBITDA margins in the 15% to 17% range. We also remain on the path to reduce our net leverage ratio to approximately 2X by the end of this year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HBIO:
- Harvard Bioscience Announces Second Quarter 2023 Financial Results
- Harvard Bioscience to Present at Sidoti Virtual Investor Conference on August 16, 2023
- Harvard Bioscience Schedules Second Quarter 2023 Earnings Conference Call for August 8, 2023 at 8:00 AM ET
- Is HBIO a Buy, Before Earnings?
- Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes
